European CHMP recommends approval of licence extension of romiplostim (Nplate)

The licence extension is for treatment of primary immune thrombocytopenia (ITP) in adults and treatment of chronic primary ITP in paediatric patients aged one year and older who are refractory to other treatments (e.g. corticosteroids, immunoglobulins).

Source:

European Medicines Agency